i refer to quotes from the CEO, the first one in the Stock-head...

i refer to quotes from the CEO, the first one in the Stock-head article, the other in AGM:

“So now, as long as we jump through the right hoops, and we do the right studies, the expectation is we should get through the FDA 510k application, which should be around late March.
”Regan says the company has enough cash right now to get through and beyond an FDA approval."

AND

"FY2023 saw an average monthly net cash burn of $1.26 million and a closing cash position at 30 June of $20.1
million."

As others have remarked IMO the reimbursement of staff seems very high for the stage of the development of the company.

Any slippage with the FDA could impact cash balance, and whilst trading volume more recently has improved, IMO its lack of liquidity could impact the possibility of a looming CR.

If everything went right, and FDA approval is achieved soon then AYA could be a big winner. If time slips before approval then the cash burn will be relevant. I doubt the board wouldn't have thoughts of another top up in the coming months.